Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure

Why Alnylam Pharmaceuticals Stock Is Back in Focus

Alnylam Pharmaceuticals (ALNY) moved sharply higher after a late stage trial for a competing transthyretin amyloid cardiomyopathy treatment from AstraZeneca and Ionis Pharmaceuticals failed, shifting investor attention toward Alnylam’s ATTR portfolio.

See our latest analysis for Alnylam Pharmaceuticals.

That ATTR news lands on top of a mixed year for Alnylam Pharmaceuticals, with the share price at $312.79, a year to date share price decline of 21.84%, a 5.07% 1 month share price gain and a 5 year total shareholder return of 81.91%. Taken together, these figures indicate that longer term holders remain ahead even as sentiment has recently been reset.

If Alnylam’s ATTR story has your attention, this could be a good moment to see what else is moving in healthcare AI. You can start with our 40 healthcare AI stocks

Bulls see Alnylam Pharmaceuticals as a reinforced ATTR leader after the recent competitor setback, while bears see a stock already pricing in much of that benefit, so which side do the current valuation markers support next?

Most Popular Narrative: 28% Undervalued

With Alnylam Pharmaceuticals closing at $312.79 versus a narrative fair value of $434.72, the most followed storyline frames the stock as meaningfully undervalued using a 7.33% discount rate.

The rapid and robust uptake of AMVUTTRA for ATTR-CM in its first full quarter post-approval, combined with near-universal first-line payer access and minimal patient out-of-pocket costs, indicates a much larger addressable market for Alnylam's RNAi therapies as diagnostics and disease awareness improve, supporting sustained double-digit revenue growth.

Read the complete narrative.

Curious what sits behind that gap between price and fair value? This narrative leans on faster earnings growth, rising margins and a richer future earnings multiple.

Result: Fair Value of $434.72 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Alnylam Pharmaceuticals still faces key risks, including pressure on AMVUTTRA pricing and margins, as well as heavy reliance on the TTR franchise if execution stumbles.

Find out about the key risks to this Alnylam Pharmaceuticals narrative.

Another View: What Alnylam Pharmaceuticals’ Earnings Multiple Is Telling You

There is a catch to the Alnylam Pharmaceuticals undervaluation story on future cash flows. On today’s numbers, the stock trades on a P/E of 77.6x, versus a fair ratio of 34.6x, the US Biotechs industry at 17.8x and peers at 30.4x, which points to meaningful valuation risk if expectations cool.

If you care more about what current earnings and peer comparisons are signaling, our valuation breakdown can help you pressure test whether this premium still feels comfortable for your own risk tolerance See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and caution around Alnylam Pharmaceuticals, it makes sense to inspect the details yourself and decide where you stand. To see what investors are highlighting on the positive side, review the 4 key rewards

Looking for more investment ideas beyond Alnylam Pharmaceuticals?

If Alnylam Pharmaceuticals has sharpened your focus, do not stop here. The wider market holds other stocks that could suit your goals and risk comfort.

• Target reliable cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (47 results) that may better align with your preference for financial strength.
• Hunt for potential value opportunities by checking the 44 high quality undervalued stocks that screens for stocks offering quality at prices that may look appealing.
• Spot potential early stage opportunities through the 20 elite penny stocks with strong financials where smaller companies with stronger financials stand out from the crowd.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com